ABBN.SW: $86.06 ▼ -0.04 (-0.05%)ASML.AS: $1,565.80 ▲ 5.00 (0.32%)ENR.DE: $160.10 ▼ -2.40 (-1.48%)GLEN.L: $535.70 ▲ 0.40 (0.07%)IFX.DE: $81.13 ▲ 0.57 (0.71%)NOKIA.HE: $12.20 ▲ 0.20 (1.67%)RIO.L: $7,278.00 ▲ 14.00 (0.19%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

TransMedics Group, Inc.

TMDX - NASDAQ

Identifiants & Marche

Ticker TMDX
ISIN US89377M1099
CIK 0001756262
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Medical - Devices

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.